Moberg Pharma (Q3 Initial take): Market shares rise further and a clear beat as Israel launches - Redeye

Redeye provides its initial take on Moberg Pharma's Q3 report, with sales and profitability well ahead of our expectations. Sales grew 44% YoY and Terclara®'s market shares in Sweden and Norway rose further from Q2. Israel was launched in September as guided, and first deliveries to Karo Healthcare remain on track for around year-end. We expect positive estimate revisions, driven mainly by the sales beat.
Länk till analysen i sin helhet: https://www.redeye.se/research/1192789/moberg-pharma-q3-initial-take-market-shares-rise-further-and-a-clear-beat-as-israel-launches?utm_source=finwire&utm_medium=RSS


